Key PointsModerna's stock has skyrocketed on exciting results from its personalized cancer vaccine.

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Fintel reports that on October 6, 2026, Barclays upgraded their outlook for Qiagen N.V. (NYSE:QGEN) (LSE:0RLT) from Equal-Weight to Overweight.Qiagen N.V., headquartered in Venlo, the Netherlands, is a prominent global provider in the field of Sample to Insight solutions, primari

Barclays Upgrades Qiagen N.V. to Overweight from Equal-Weight

In recent trading, shares of Qiagen NV (Symbol: QGEN) have crossed above the average analyst 12-month target price of $45.40, changing hands for $45.79/share.  When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation,

QGEN Crosses Above Average Analyst Target

The ROBO Global Healthcare Technology and Innovation ETF is seeing unusually high volume in afternoon trading Friday, with over 454,000 shares traded versus three month average volume of about 27,000.  Shares of HTEC were trading flat on the day.

Components of that ETF with the

Friday's ETF with Unusual Volume: HTEC  

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

The S&P 500 Index ($SPX ) (SPY ) closed up by +1.14% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.61%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.73%.  September E-mini S&P futures (ESU26 ) rose +1.10%, and September E-mini...

Stocks Settle Sharply Higher as Crude Oil and Bond Yields Fall

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Qiagen N.V. News